Key result
Intranasal bumetanide achieves decongestion in a patient with oral diuretic resistance, bridging to successful TMVR.
Why the study?
Patients with advanced valvular disease frequently experience oral diuretic resistance.
Population
One 76-year-old woman with severe mitral regurgitation, recurrent volume overload, and oral diuretic resistance
Comparison
Intranasal bumetanide
Design
Case report
Authors
Loading...
May bridge decongestion in select diuretic-resistant valvular cases; leaves open need for prospective validation.
Case Report (n=1)
Intranasal bumetanide may serve as an effective nonoral diuretic bridge to advanced structural interventions in patients with oral diuretic resistance, allowing for home administration and avoidance of hospitalizations.
Rushakoff et al. (2026) conducted a case report in Diuretic-Resistant Heart Failure and severe mitral regurgitation (n=1). Intranasal bumetanide was evaluated on Decongestion allowing for advanced evaluation and successful transcatheter mitral valve replacement. Intranasal bumetanide successfully achieved decongestion in a patient with oral diuretic resistance, serving as an effective bridge to transcatheter mitral valve replacement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: